Abstract
Medullary breast carcinoma (MBC) is a rare tumor, representing 3% to 5% of invasive breast carcinomas. The World Health Organization defines it as a well-circumscribed invasive tumor, composed of poorly differentiated cells, arranged in sheets, without gland formation and a scarce collagen stroma with the presence of a very prominent lymphoplasmacytic infiltrate.
Highlights
Medullary breast carcinoma (MBC) is a rare tumor, representing 3% to 5% of invasive breast carcinomas [1,2]
There are more CD8positive than CD4-positive T-cell lymphocytes within the tumor cell nests, unlike the proportions found in ductal carcinoma
Another relevant and interesting aspect is that most MBCs are characterized by the negative expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) [8], by which is called this subtype of breast carcinoma, triple negative [9]
Summary
Medullary breast carcinoma (MBC) is a rare tumor, representing 3% to 5% of invasive breast carcinomas [1,2]. This brief note is intended to comment on the prognosis and survival of medullary breast carcinoma and thereby motivate new and necessary research in this field, since the determination of these factors is important to identify patients with greater risk of disease recurrence and death, these patients being able to benefit from more aggressive treatment.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
